Use of naloxone for producing a medicament devoid of non-oral abuse-potential for humans, where the medicament contains a psychotropic substance, which is useful for treating attention deficit hyperactivity disorder
CA2646899A1
Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders
DE102007009888A1
Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder
EP1897544A1
Opioid agonist and antagonist combinations
DE102006016990A1
Use of baclofen compounds to treat dependence on gamma-hydroxybutyrate or its analogs
DE102006016991A1
Use of a composition comprising kappa opioid receptor antagonist e.g. for producing a drug for the treatment of dissociative disorders in humans
DE102006015734A1
Combination preparations of modafinil, ritalin and topiramate and their derivatives for the treatment of cocaine addiction and / or impulse control disorder
DE102006015733A1
Use of buprenorphine compounds to treat emotionally unstable personality disorder, alcohol dependence or multiple substance dependence
EP1810669A1
Application form for burprenorphine
EP1810670A1
Combination of Polamidone and Naloxone for the treatment of drug addiction
EP1810714A1
Use of a combination of heroin and naloxon for drug substitution
EP1810678A1
Use of morphine and naloxone for drug substitution
